The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ichikawa, H.
Right arrow Articles by Aggarwal, B. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ichikawa, H.
Right arrow Articles by Aggarwal, B. B.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
The Journal of Immunology, 2005, 174: 7383-7392.
Copyright © 2005 by The American Association of Immunologists

Identification of a Novel Blocker of I{kappa}B{alpha} Kinase That Enhances Cellular Apoptosis and Inhibits Cellular Invasion through Suppression of NF-{kappa}B-Regulated Gene Products1

Haruyo Ichikawa*, Yasunari Takada*, Akira Murakami{dagger} and Bharat B. Aggarwal2,*

* Cytokine Research Section, Department of Experimental Therapeutics, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030; and {dagger} Division of Food Science and Biotechnology, Graduate School of Agriculture, Kyoto University, Kyoto, Japan

1'-Acetoxychavicol acetate (ACA), extracted from rhizomes of the commonly used ethno-medicinal plant Languas galanga, has been found to suppress chemical- and virus-induced tumor initiation and promotion through a poorly understood mechanism. Because several genes that regulate cellular proliferation, carcinogenesis, metastasis, and survival are regulated by activation of the transcription factor NF-{kappa}B, we postulated that ACA might mediate its activity through modulation of NF-{kappa}B activation. For this report, we investigated the effect of ACA on NF-{kappa}B and NF-{kappa}B-regulated gene expression activated by various carcinogens. We found that ACA suppressed NF-{kappa}B activation induced by a wide variety of inflammatory and carcinogenic agents, including TNF, IL-1{beta}, PMA, LPS, H2O2, doxorubicin, and cigarette smoke condensate. Suppression was not cell type specific, because both inducible and constitutive NF-{kappa}B activations were blocked by ACA. ACA did not interfere with the binding of NF-{kappa}B to the DNA, but, rather, inhibited I{kappa}B{alpha} kinase activation, I{kappa}B{alpha} phosphorylation, I{kappa}B{alpha} degradation, p65 phosphorylation, and subsequent p65 nuclear translocation. ACA also inhibited NF-{kappa}B-dependent reporter gene expression activated by TNF, TNFR1, TNFR-associated death domain protein, TNFR-associated factor-2, and I{kappa}B{alpha} kinase, but not that activated by p65. Consequently, ACA suppressed the expression of TNF-induced NF-{kappa}B-regulated proliferative (e.g., cyclin D1 and c-Myc), antiapoptotic (survivin, inhibitor of apoptosis protein-1 (IAP1), IAP2, X-chromosome-linked IAP, Bcl-2, Bcl-xL, Bfl-1/A1, and FLIP), and metastatic (cyclooxygenase-2, ICAM-1, vascular endothelial growth factor, and matrix metalloprotease-9) gene products. ACA also enhanced the apoptosis induced by TNF and chemotherapeutic agents and suppressed invasion. Overall, our results indicate that ACA inhibits activation of NF-{kappa}B and NF-{kappa}B-regulated gene expression, which may explain the ability of ACA to enhance apoptosis and inhibit invasion.




This article has been cited by other articles:


Home page
BloodHome page
A. B. Kunnumakkara, A. S. Nair, K. S. Ahn, M. K. Pandey, Z. Yi, M. Liu, and B. B. Aggarwal
Gossypin, a pentahydroxy glucosyl flavone, inhibits the transforming growth factor beta-activated kinase-1-mediated NF-{kappa}B activation pathway, leading to potentiation of apoptosis, suppression of invasion, and abrogation of osteoclastogenesis
Blood, June 15, 2007; 109(12): 5112 - 5121.
[Abstract] [Full Text] [PDF]


Home page
Annals of Clinical & Laboratory ScienceHome page
R. E. Brown, D. Tan, J. S. Taylor, M. Miller, J. W. Prichard, and M. M. Kott
Morphoproteomic Confirmation of Constitutively Activated mTOR, ERK, and NF-kappaB Pathways in High Risk Neuro-blastoma, with Cell Cycle and Protein Analyte Correlates
Ann. Clin. Lab. Sci., January 1, 2007; 37(2): 141 - 147.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
S. J. Braeuer, C. Buneker, A. Mohr, and R. M. Zwacka
Constitutively Activated Nuclear Factor-{kappa}B, but not Induced NF-{kappa}B, Leads to TRAIL Resistance by Up-Regulation of X-Linked Inhibitor of Apoptosis Protein in Human Cancer Cells
Mol. Cancer Res., October 1, 2006; 4(10): 715 - 728.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
H. Ichikawa, M. S. Nair, Y. Takada, D.B. A. Sheeja, M.A. S. Kumar, O. V. Oommen, and B. B. Aggarwal
Isodeoxyelephantopin, a Novel Sesquiterpene Lactone, Potentiates Apoptosis, Inhibits Invasion, and Abolishes Osteoclastogenesis through Suppression of Nuclear Factor-{kappa}B (NF-{kappa}B) Activation and NF-{kappa}B-Regulated Gene Expression.
Clin. Cancer Res., October 1, 2006; 12(19): 5910 - 5918.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. K. Sandur, H. Ichikawa, G. Sethi, K. S. Ahn, and B. B. Aggarwal
Plumbagin (5-Hydroxy-2-methyl-1,4-naphthoquinone) Suppresses NF-{kappa}B Activation and NF-{kappa}B-regulated Gene Products Through Modulation of p65 and I{kappa}B{alpha} Kinase Activation, Leading to Potentiation of Apoptosis Induced by Cytokine and Chemotherapeutic Agents
J. Biol. Chem., June 23, 2006; 281(25): 17023 - 17033.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
H. Ichikawa, Y. Takada, S. Shishodia, B. Jayaprakasam, M. G. Nair, and B. B. Aggarwal
Withanolides potentiate apoptosis, inhibit invasion, and abolish osteoclastogenesis through suppression of nuclear factor-{kappa}B (NF-{kappa}B) activation and NF-{kappa}B-regulated gene expression.
Mol. Cancer Ther., June 1, 2006; 5(6): 1434 - 1445.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
H. Ichikawa, A. Murakami, and B. B. Aggarwal
1'-Acetoxychavicol Acetate Inhibits RANKL-Induced Osteoclastic Differentiation of RAW 264.7 Monocytic Cells by Suppressing Nuclear Factor-{kappa}B Activation
Mol. Cancer Res., April 1, 2006; 4(4): 275 - 281.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
Y. Takada, H. Ichikawa, V. Badmaev, and B. B. Aggarwal
Acetyl-11-Keto-beta-Boswellic Acid Potentiates Apoptosis, Inhibits Invasion, and Abolishes Osteoclastogenesis by Suppressing NF-{kappa}B and NF-{kappa}B-Regulated Gene Expression.
J. Immunol., March 1, 2006; 176(5): 3127 - 3140.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
H. Ichikawa and B. B. Aggarwal
Guggulsterone Inhibits Osteoclastogenesis Induced by Receptor Activator of Nuclear Factor-{kappa}B Ligand and by Tumor Cells by Suppressing Nuclear Factor-{kappa}B Activation
Clin. Cancer Res., January 15, 2006; 12(2): 662 - 668.
[Abstract] [Full Text] [PDF]


Home page
Annals of Clinical & Laboratory ScienceHome page
R. E. Brown, P. L. Zhang, M. Lun, S. Zhu, P. K. Pellitteri, A. Law, G. C. Wood, and T. L. Kennedy
Morphoproteomic and Pharmacoproteomic Rationale for mTOR Effectors as Therapeutic Targets in Head and Neck Squamous Cell Carcinoma
Ann. Clin. Lab. Sci., January 1, 2006; 36(3): 273 - 282.
[Abstract] [Full Text] [PDF]


Home page
Annals of Clinical & Laboratory ScienceHome page
F. Lin, P. L. Zhang, X. J. Yang, J. W. Prichard, M. Lun, and R. E. Brown
Morphoproteomic and Molecular Concomitants of an Overexpressed and Activated mTOR Pathway in Renal Cell Carcinomas
Ann. Clin. Lab. Sci., January 1, 2006; 36(3): 283 - 293.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.